All In Biotech

Drug Trial Radar · NCT05497635

A Study of STSA-1002 in Healthy Subjects

A Randomized,Double-blind, Placebo-controlled, Multiple Ascending-Dose Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of STSA-1002 Injection in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Apr 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

26

Actual

Start

Oct 14, 2022

Primary completion

Apr 6, 2023

Study completion Apr 6, 2023

Sponsor

Sponsor type
Industry
First posted
Aug 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a Phase Ib, randomized, double-blind, placebo-controlled, multiple dose, dose escalation safety, tolerability,pharmacokinetic and pharmacodynamic study of STSA-1002 injection in healthy subjects. A total of 26 healthy subjects were enrolled in three dosage groups.

Conditions

  • Healthy Subject

Interventions

  • STSA-1002 InjectionDrug

    Intravenous injection

  • PlaceboDrug

    Intravenous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events、Clinically Significant Laboratory Abnormalities、Clinically Significant Electrocardiogram、Vital Signs And Physical Examination Abnormalities.Time frame: Up to Study Day 56
  2. Maximum plasma concentration (Cmax)Time frame: From Day 0 to Day 56
  3. Area under the plasma concentration-time curve from time 0 to the collection time point t of the last measurable concentration (AUC0-t)Time frame: From Day 0 to Day 56
  4. Area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞)Time frame: From Day 0 to Day 56
  5. Time of maximum concentration (Tmax)Time frame: From Day 0 to Day 56
  6. Elimination half-life (t1/2)Time frame: From Day 0 to Day 56
  7. Mean residence time (MRT)Time frame: From Day 0 to Day 56
  8. Clearance (CL)Time frame: From Day 0 to Day 56
  9. Apparent volume of distribution (Vz)Time frame: From Day 0 to Day 56
  10. Maximum Concentration of the Analyte in Plasma at steady state(Cmax, ss)Time frame: From Day 0 to Day 56
  11. Minimum Measured Concentration of the Analyte in Plasma at Steady State(Cmin, ss)Time frame: From Day 0 to Day 56
  12. Time-averaged concentration at steady state(Cav, ss)Time frame: From Day 0 to Day 56
  13. Area under the concentration curve from time 0 extrapolate to infinite time(AUCinf,ss)Time frame: From Day 0 to Day 56
  14. Degree of fluctuation(DF)Time frame: From Day 0 to Day 56
  15. Accumulation factorTime frame: From Day 0 to Day 56

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Shijitan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • The Second Affiliated Hospital Of Xingtai Medical College

    Xingtai, Hebei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.